Kwality Pharmaceuticals has secured approval from the Review Committee on Genetic Manipulation (RCGM) to commence pre-clinical toxicity studies for its recombinant Erythropoietin product, 10,000 1U/mL, developed in its Biologics Unit. Erythropoietin is a critical therapeutic used to treat anemia associated with chronic kidney disease (CKD).
This milestone marks a significant step forward in its commitment to expanding its biologics portfolio and addressing critical healthcare needs. With this approval, the company is on track to complete the pre-clinical studies and is diligently preparing for the commercialization of the product in the next fiscal.
Kwality Pharmaceuticals (formerly Kwality Pharmaceuticals) is a pharmaceutical formation company.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1837.15 |
| Dr. Reddys Lab | 1271.55 |
| Cipla | 1353.85 |
| Zydus Lifesciences | 1070.90 |
| Lupin | 2351.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: